Adult CIRB - Early Phase Emphasis Meeting Agenda

April 21, 2020

I Continuing Review

10218, A Phase 1b Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma (Protocol Version Date 08/19/19)

II Continuing Review

10222, A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors (Protocol Version Date 02/05/20)

III Continuing Review

10240, Phase II Study of XL184 (cabozantinib) in combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after One Prior VEGFR-Targeted Therapy (Protocol Version Date 03/02/20)

IV New Study - Initial Review

10330, A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma (Protocol Version Date 02/27/20)

V New Study - Initial Review

10382, A Phase I/II Trial Evaluating the Safety and Efficacy of Eribul in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer (Protocol Version Date 03/12/20)
VI Amendment

10030. A phase 1 study of blinatumomab in combination with checkpoint inhibitor(s) of PD-1 (nivolumab) or both PD-1 (nivolumab) and CTLA-4 (ipilimumab) in patients with poor-risk, relapsed or refractory CD19+ precursor B-lymphoblastic leukemia (Protocol Version Date 03/11/20)